Meeder Asset Management Inc Aerie Pharmaceuticals Inc Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$12.0 - $16.13 $144 - $193	-12 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $544 - $1,173	-46 Reduced 79.31%	12 $0
Q4 2019 Feb 13, 2020	SELL	$17.72 - $25.1 $22,911 - $32,454	-1,293 Reduced 95.71%	58 $1,000
Q3 2019 Oct 17, 2019	BUY	$18.41 - $28.0 $2,816 - $4,284	153 Added 12.77%	1,351 $26,000
Q2 2019 Aug 05, 2019	BUY	$28.97 - $48.21 $3,997 - $6,652	138 Added 13.02%	1,198 $35,000
Q1 2019 Apr 16, 2019	BUY	$36.32 - $49.25 $22,046 - $29,894	607 Added 134.0%	1,060 $50,000
Q4 2018 Jan 17, 2019	BUY	$33.0 - $60.04 $14,949 - $27,198	453 New	453 $16,000
Q1 2018 May 03, 2018	SELL	$51.15 - $61.0 $153 - $183	-3 Closed	0 $0
Q4 2017 Feb 02, 2018	BUY	$50.85 - $65.1 $152 - $195	3	3 $0

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.